Overview
Camcevi ETM is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with advanced prostate cancer. Camcevi ETM is also known by its drug name, leuprolide.

Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. It works by initially increasing, then significantly lowering the levels of testosterone in the body. Reduced testosterone helps slow or stop the growth of prostate cancer cells.

How do I take it?
Prescribing information states that Camcevi ETM is given as a subcutaneous (under the skin) injection. Injections are typically given every three months. The medication should be administered by a healthcare professional,  exactly as prescribed.

Side effects
Common side effects of Camcevi ETM include increased triglycerides, elevated liver enzymes (alanine aminotransferase and aspartate aminotransferase), hot flushes, hypertension (high blood pressure), low hemoglobin, increased sodium and potassium levels, injection site reactions, weight gain, low neutrophils, and decreased white blood cell count.

Rare but serious side effects may include tumor flare (a temporary worsening of prostate cancer symptoms at the beginning of treatment), hyperglycemia (high blood sugar) or new-onset diabetes, cardiovascular problems such as heart attack, sudden cardiac death, and stroke, QT interval prolongation (a type of abnormal heart rhythm), seizures, and severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). Camcevi ETM may also harm an unborn baby and affect fertility.

For more information about this treatment, visit:
Camcevi ETM (Leuprolide) Injectable Emulsion, for Subcutaneous Use — Foresee Pharmaceuticals